Drug intelligence / Profile preview

TJX-7

Development stage: Preclinical
Lead developer: I-MAB

Overview

TJX-7 is an investigational **CXCL13 inhibitor** being developed by **I-Mab Biopharma** for immune system-related diseases. Publicly available information indicates that the program is at the **preclinical** stage and is intended to modulate the **C-X-C motif chemokine 13** signaling axis, a pathway involved in B-cell trafficking, lymphoid tissue organization, and inflammatory immune responses. The precise molecular format, active ingredient, route of administration, formulation, and specific disease indications have not been publicly disclosed.

Targets

CXCL13 (C-X-C motif chemokine ligand 13)

Beyond the preview

Go deeper on TJX-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJX-7.

Explore the full profile